Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia
Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
Hydroxychloroquine has been reported to have a clinically significant effect on the platelet
count in systemic lupus thrombocytopenia. Its action may be due to its immune modulator
effect. Immune thrombocytopenia (ITP) is known as an immune-mediated acquired disease
characterized by transient or persistent decrease of the platelet count. However, refractory
ITP is lacking of effective treatments and the efficacy of decitabine in ITP remains poorly
understood. Data from this study may provide some idea of Hydroxychloroquine in the treatment
of ITP in comparison to other lines of treatment as detected by the standardized definitions.